Renowned Speakers
Massimo Cecaro
Editor in Chief Occupational Medicine & Health Affairs, Director of Accredited Training Centre University of Camerino Italy
Dr. Dana Haddad
Head of Breast Imaging HealthBay Polyclinic UAE
Dr.Kazuko Tatsumura
Director Gaia Holistic Health USA USA
Lori A. Loan
Associate Professor University of Alabama USA University of Alabama USA
Liane Deligdisch
Professor The Icahn School of Medicine at Mount Sinai USA
Diana Anderson
Professor University of Bradford UK
Dr.Khalid Shah
Director Center for Stem Cell and Translational Immunotherapy, USA
Dr. Dipali Sharma
Professor Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins USA
Recommended Global Medical Webinars & Conferences
Preventive Oncology 2026
Welcome Message
On behalf of the Organizing Committee, it is our great honor and pleasure to warmly welcome our distinguished keynote speakers, respected delegates, and valued exhibitors to the 39th Conference on Preventive Oncology and Diagnostic Cancer, to be held on July 27–28, 2026, in Rome, Italy.
Under the theme “Advancing Cancer Prevention and Early Diagnosis for a Healthier Future,” this conference brings together leading scientists, clinicians, researchers, healthcare professionals, industry partners, and policy makers from around the world. The meeting serves as a dynamic international forum for the exchange of knowledge, presentation of groundbreaking research, and discussion of emerging trends in cancer prevention, early detection, and diagnostic innovations.
The scientific program has been carefully designed to encourage interdisciplinary dialogue, promote collaborative research, and highlight innovative strategies that can translate scientific discoveries into improved clinical practice and public health outcomes. We believe that the collective expertise and diverse perspectives of our participants will inspire meaningful discussions and contribute to shaping the future of oncology and cancer diagnostics.
In addition to the scientific sessions, we hope this conference provides ample opportunities for networking, professional growth, and the development of lasting collaborations. Set in the historic and culturally rich city of Rome, the conference also offers a unique environment for cultural exchange and informal interaction.
We sincerely thank all speakers, delegates, exhibitors, sponsors, and organizing partners for their invaluable contributions. We wish you a productive, engaging, and memorable conference experience.
About the Preventive Oncology 2026
The 39th Conference on Preventive Oncology and Diagnostic Cancer is a leading international scientific meeting scheduled for July 27–28, 2026, in Rome, Italy. The conference is dedicated to advancing research, knowledge exchange, and practical solutions in the areas of cancer prevention, early detection, and diagnostic innovation.
This global forum brings together researchers, clinicians, public health experts, academicians, industry professionals, and policy makers to discuss current challenges and emerging opportunities in preventive oncology. The conference aims to highlight innovative approaches that reduce cancer risk, improve early diagnosis, and enhance patient outcomes through evidence-based strategies and technological advancements.
The scientific program covers a broad spectrum of topics, including cancer epidemiology, biomarkers and screening strategies, precision medicine, molecular and genetic diagnostics, lifestyle and environmental factors in cancer prevention, artificial intelligence in oncology diagnostics, and public health interventions. Through keynote lectures, plenary sessions, oral and poster presentations, participants will engage in meaningful scientific dialogue and interdisciplinary collaboration.
In addition to the academic sessions, the conference provides valuable opportunities for networking, professional development, and collaboration between academia, healthcare institutions, and industry. The historic city of Rome offers an inspiring setting that encourages cultural exchange and informal interaction among participants.
The Preventive Oncology 2026 Conference reflects a shared global commitment to advancing cancer prevention and diagnostic excellence, fostering innovation, and shaping the future of oncology for the benefit of patients and communities worldwide.
Why Attend Preventive Oncology 2026?
The 39th Conference on Preventive Oncology and Diagnostic Cancer offers a unique opportunity to engage with global leaders and experts dedicated to advancing cancer prevention and early diagnosis. Attending this conference allows participants to stay at the forefront of scientific innovation while contributing to meaningful discussions that shape the future of oncology.
- Gain insights into the latest advances in cancer prevention, early detection, and diagnostic technologies
- Learn from renowned keynote speakers and global experts in preventive oncology and cancer diagnostics
- Explore cutting-edge research, clinical practices, and public health strategies shaping the future of oncology
- Present your research through oral or poster presentations and receive valuable expert feedback
- Network with international researchers, clinicians, public health professionals, and industry leaders
- Discover innovative products and solutions showcased by leading exhibitors and technology providers
- Engage in interactive sessions, panel discussions, and interdisciplinary collaborations
- Enhance your professional visibility and expand global collaboration opportunities
- Stay updated on emerging trends, including precision medicine, biomarkers, genomics, and AI in cancer diagnostics
- Experience a high-quality scientific event in the historic and inspiring city of Rome, Italy
Target Audience
- Oncologists and cancer specialists
- Preventive medicine physicians
- Diagnostic and clinical pathologists
- Radiologists and imaging specialists
- Cancer researchers and scientists
- Public health professionals and epidemiologists
- Molecular biologists and geneticists
- Healthcare practitioners and primary care physicians
- Academicians, educators, and students
- Pharmaceutical, biotechnology, and medical device industry professionals
- Diagnostic laboratory professionals
- Healthcare policy makers and administrators
- Clinical research organizations and data scientists
- Industry sponsors and exhibitors
Sessions and Tracks
Session 01: Molecular Advances in Preventive Oncology
Molecular foundations are reshaping preventive oncology by enabling earlier identification of individuals at elevated cancer risk before clinical symptoms appear. Advances in genomics, epigenomics, transcriptomics, and proteomics now support highly sensitive detection of pre-malignant alterations and inherited susceptibility patterns. Hereditary cancer syndromes, germline mutation testing, and the integration of high-penetrance and moderate-risk genes into clinical workflows are strengthening personalized prevention strategies. The expanding use of polygenic risk scores, supported by large population datasets, allows refinement of individualized screening intervals and targeted surveillance models. Liquid biopsy technologies, including circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), microRNA signatures, and extracellular vesicles, are transforming noninvasive early detection and minimal residual disease monitoring. Epigenetic biomarkers such as DNA methylation signatures and chromatin modification patterns further enhance sensitivity in early-stage cancer identification. Preventive interventions including chemoprevention, targeted prophylactic therapies, immunoprevention strategies, and vaccine development are increasingly aligned with molecular risk profiling. Translational research pipelines emphasize analytical validation, reproducibility, and clinical utility to ensure safe implementation of emerging biomarkers. Ethical considerations including genetic counseling, informed consent, and responsible communication of probabilistic risk remain central to integrating molecular diagnostics into preventive frameworks. By combining molecular biology, predictive analytics, and precision medicine approaches, proactive cancer prevention strategies are shifting oncology from reactive treatment models toward anticipatory, individualized care designed to reduce long-term cancer burden.
Session 02: Integrated Diagnostic Strategies for Early Cancer
The convergence of multidisciplinary diagnostic technologies is enhancing the accuracy, efficiency, and personalization of early cancer detection. Multimodal platforms integrating molecular profiling, advanced imaging, digital pathology, and artificial intelligence–driven analytics are creating cohesive diagnostic ecosystems capable of identifying malignancies at earlier stages. Multi-cancer early detection assays capable of detecting multiple tumor types from a single blood sample are expanding screening possibilities beyond organ-specific approaches. Radiomics and imaging biomarkers, when combined with genomic and proteomic signatures, improve sensitivity and specificity while reducing diagnostic uncertainty. Digital pathology systems with automated tumor grading and AI-assisted slide interpretation are minimizing variability and accelerating clinical workflows. Innovations in point-of-care testing, wearable biosensors, and remote monitoring technologies are expanding access to preventive services, particularly in resource-limited settings. Seamless interoperability between laboratory systems, imaging platforms, and electronic health records supports integrated clinical decision-making. Consideration is given to challenges such as overdiagnosis, incidental findings, and patient communication complexities associated with advanced screening tools. Alignment of laboratory science, digital infrastructure, and clinical expertise ensures that diagnostic advancements translate into meaningful patient outcomes. Comprehensive integration of these technologies establishes a patient-centered early detection framework designed to improve survival while optimizing healthcare efficiency.
Session 03: Risk-Based Screening and Precision Prevention
Risk-adapted screening frameworks are redefining preventive oncology by tailoring early detection strategies to individual risk profiles. Predictive models incorporating demographic variables, lifestyle exposures, environmental influences, family history, and molecular biomarkers enable dynamic stratification of populations into appropriate surveillance pathways. Personalized screening intervals and modality selection enhance detection rates while minimizing unnecessary interventions. Balancing sensitivity and specificity remains critical to reducing false positives, avoidable biopsies, and psychological distress. Addressing disparities in screening participation through culturally responsive education, community outreach programs, and mobile diagnostic services improves equity in preventive care delivery. Health economic modeling and cost-effectiveness analyses support sustainable implementation of national and regional screening initiatives. Implementation science methodologies guide translation of evidence-based screening recommendations into real-world healthcare systems. Behavioral and psychosocial considerations, including shared decision-making, adherence support, and risk perception management, are integral to effective preventive strategies. Integration of epidemiological data, molecular risk profiling, public health planning, and healthcare system coordination establishes a precision prevention model capable of reducing cancer incidence and mortality while maintaining ethical and economic sustainability.
Session 04: Emerging Technologies in Cancer Diagnostics
Emerging technologies are revolutionizing early cancer detection by enabling the identification of pre-malignant and early malignant changes with unprecedented precision. Single-cell sequencing, spatial transcriptomics, and multi-omics integration allow researchers and clinicians to map cellular heterogeneity, detect rare oncogenic events, and understand tumor evolution at the earliest stages. Advanced proteomics and metabolomics profiling further enhance the ability to detect subtle molecular shifts that may precede overt cancer development. Nanotechnology-based biosensors and microfluidic platforms are enabling rapid, highly sensitive biomarker analysis with minimal invasiveness. Integration of radiomics and pathomics into unified diagnostic pipelines allows comprehensive characterization of tumors from noninvasive imaging combined with digital pathology, improving predictive accuracy and treatment planning. Artificial intelligence and machine learning algorithms are increasingly applied to detect subtle patterns across complex datasets, from imaging scans to molecular profiles, facilitating early identification of high-risk individuals. Longitudinal monitoring using real-world data and wearable technologies supports adaptive surveillance strategies, enabling dynamic risk assessment over time. Ethical considerations, including validation standards, regulatory compliance, and equitable access, are critical to ensuring that these advanced diagnostics are implemented safely and responsibly. By combining cutting-edge laboratory innovations, computational analytics, and translational research, these emerging technologies offer a transformative approach to preventive oncology, enabling proactive intervention and improved outcomes while reducing cancer-related morbidity and mortality.
Session 05: Biomarker Validation and Clinical Translation
The development and translation of cancer biomarkers into clinical practice require rigorous validation and quality assurance frameworks to ensure reliability, reproducibility, and clinical utility. Biomarker pipelines include discovery, analytical validation, clinical validation, and demonstration of clinical effectiveness, with each stage requiring robust methodologies to reduce false positives and false negatives. Standardization across laboratories, including harmonized assay protocols, quality control measures, and proficiency testing, ensures that biomarkers perform consistently in diverse settings. Integration of biomarkers into clinical workflows supports risk-adapted prevention, early detection, and treatment decision-making, particularly when combined with imaging and molecular profiling. Biobanking infrastructure, longitudinal cohort studies, and real-world evidence collection are critical for validating biomarkers across populations and understanding long-term outcomes. Regulatory pathways and ethical considerations, including informed consent for genetic testing and data privacy, underpin safe translation of biomarkers into clinical use. Companion diagnostics and predictive biomarkers enhance preventive strategies by identifying individuals who are most likely to benefit from targeted interventions or chemopreventive therapies. Data integration across laboratory systems, electronic health records, and clinical decision-support platforms facilitates a seamless diagnostic continuum. By bridging discovery science with translational and implementation frameworks, validated biomarkers serve as essential tools for precision prevention and personalized early cancer detection strategies.
Session 06: Policy, Systems, and Sustainable Cancer Prevention
Sustainable cancer prevention requires the alignment of health policy, healthcare systems, and population-level interventions to embed early detection and risk reduction into routine care. National and regional frameworks must address reimbursement models, funding mechanisms, and public–private partnerships to support large-scale screening programs. Integration of preventive oncology into primary care, multidisciplinary teams, and community health initiatives ensures coordination across clinicians, genetic counselors, radiologists, and public health professionals. Workforce development, infrastructure enhancement, and training in emerging diagnostic technologies are critical to expanding access, especially in low-resource or underserved regions. Community engagement strategies, culturally tailored health education, and patient navigation programs increase participation in screening and adherence to preventive interventions. Digital health platforms, centralized cancer registries, and interoperable data systems enable continuous monitoring, evaluation, and real-time adjustment of preventive programs. Policy and regulatory frameworks are essential to ensure ethical implementation, equity in access, and cost-effectiveness. By combining health system planning, evidence-based guidelines, and global collaboration, sustainable preventive oncology programs can reduce cancer incidence, improve early detection rates, and strengthen long-term population health outcomes worldwide.
Session 07: AI and Predictive Analytics in Early Detection
Artificial intelligence (AI) and predictive analytics are transforming early cancer detection by enabling the analysis of complex datasets that surpass human interpretative capacity. Machine learning, deep learning, and neural network algorithms are applied across radiology, pathology, genomics, and electronic health records to identify subtle patterns indicative of early malignancy. AI-assisted mammography, low-dose CT interpretation for lung cancer, digital pathology slide analysis, and predictive risk scoring systems facilitate earlier and more accurate detection while reducing interobserver variability. Predictive models integrate longitudinal patient data, molecular biomarkers, and lifestyle factors to forecast individualized cancer risk trajectories and recommend personalized screening intervals. Federated learning approaches allow multi-institutional collaboration without compromising patient privacy, while bias mitigation strategies ensure equitable performance across diverse populations. The integration of wearable health monitoring devices, cloud-based diagnostic platforms, and real-world data further enhances the predictive capabilities of AI-driven systems. Ethical considerations including transparency, explainability, patient consent, and regulatory oversight are central to responsible AI deployment in clinical practice. By combining computational analytics with clinical insights, AI enables proactive cancer surveillance, improves diagnostic efficiency, and supports precision prevention strategies, ultimately reducing morbidity and mortality through earlier intervention and targeted monitoring.
Session 08: Community and Public Health Approaches to Prevention
Community engagement and public health integration are critical for effective cancer prevention, focusing on behavioral interventions, risk reduction, and equitable access to early detection services. Lifestyle modifications such as tobacco cessation, healthy diet, physical activity, and vaccination programs significantly reduce cancer risk at the population level. Community-based initiatives, patient navigation programs, and culturally tailored education campaigns improve screening uptake, particularly in underserved and rural populations. Integration of preventive oncology into primary care, school-based health programs, and workplace wellness initiatives supports widespread adoption of risk reduction practices. Digital health technologies, mobile applications, and telehealth platforms extend the reach of prevention programs and enable real-time monitoring and follow-up. Public health policies, environmental interventions, and long-term strategic planning further enhance population-level impact. Addressing socioeconomic, geographic, and cultural disparities ensures equitable access to preventive services and reduces health inequities. Data collection, cancer registries, and outcome monitoring facilitate program evaluation, continuous improvement, and evidence-based policy decisions. By combining behavioral science, public health strategies, and community partnerships, these approaches create sustainable frameworks for reducing cancer incidence, promoting early detection, and improving long-term health outcomes on a population scale.
Session 09: Personalized Immunoprevention and Cancer Vaccines
Advances in immunology are opening new frontiers in preventive oncology, focusing on strategies to harness the immune system to intercept cancer before it develops. Personalized immunoprevention involves tailoring vaccines or immune-based interventions to individual molecular and genetic risk profiles, targeting tumor-associated antigens or neoantigens specific to high-risk populations. The development of prophylactic cancer vaccines, such as those for virus-associated malignancies (e.g., HPV and hepatitis B), provides a model for extending immunoprevention to non-viral cancers through emerging peptide, mRNA, and dendritic cell vaccine platforms. Immune checkpoint modulation and adoptive immune therapies are being explored as preventive approaches in individuals with precancerous lesions or high-risk genetic mutations. Biomarker-guided immune monitoring enables real-time assessment of immune response and efficacy, facilitating adaptive immunoprevention strategies. Ethical, regulatory, and safety considerations, including long-term immune surveillance and risk-benefit assessment, are critical in clinical implementation. Translational research pipelines integrate preclinical models, early-phase clinical trials, and population-level studies to validate vaccine effectiveness and guide deployment strategies. Integration with public health initiatives, lifestyle interventions, and conventional screening programs ensures a multi-layered preventive framework. By leveraging precision immunology and vaccine technology, personalized immunoprevention represents a paradigm shift toward proactive cancer interception, offering the potential to significantly reduce incidence and improve population health outcomes.
Session 10: Translational Research and Global Collaboration
Global collaboration and translational research are essential to advance preventive oncology and implement innovations in early cancer detection worldwide. Translational research bridges basic scientific discoveries with clinical application, ensuring that biomarkers, diagnostic tools, and preventive interventions are validated, scalable, and effective across diverse populations. Multi-center studies, cohort analyses, and real-world data integration accelerate the development of evidence-based strategies. International collaboration supports standardization of screening protocols, data sharing, and harmonization of laboratory and diagnostic practices, enhancing reproducibility and reliability. The session emphasizes capacity building, training programs, and knowledge transfer to expand access to cutting-edge preventive technologies in low- and middle-income regions. Ethical and regulatory harmonization, including informed consent, data privacy, and equitable benefit-sharing, is central to global implementation. Policy frameworks, financing models, and public-private partnerships are critical to sustaining large-scale prevention initiatives. By integrating scientific innovation, health systems strengthening, and international cooperation, translational research accelerates the adoption of preventive oncology tools and ensures that the benefits of early detection and personalized prevention reach populations worldwide, reducing cancer burden and improving global health equity.
Session 11: Digital Health and Tele-Oncology in Preventive Cancer Care
Digital health technologies and tele-oncology are revolutionizing the delivery of preventive oncology services, extending early detection, risk assessment, and patient education beyond traditional healthcare settings. Mobile health applications, wearable biosensors, and remote monitoring devices enable continuous tracking of health metrics, lifestyle factors, and early warning signs associated with cancer risk. Integration of telemedicine platforms allows virtual consultations, genetic counseling, and follow-up care, overcoming geographic and socioeconomic barriers to access. Artificial intelligence-driven decision-support tools embedded in digital platforms provide real-time risk stratification, recommend personalized screening schedules, and facilitate timely intervention. Data from electronic health records, population registries, and patient-generated health data can be aggregated and analyzed to identify trends, improve preventive strategies, and support research initiatives. The session highlights the role of predictive modeling, machine learning, and cloud-based analytics in optimizing early detection pathways, enhancing clinical workflow, and improving resource allocation. Challenges such as data security, patient privacy, interoperability, and equitable access are addressed, along with strategies to mitigate digital health disparities. Digital literacy programs, culturally tailored user interfaces, and community engagement are critical to maximizing adoption and effectiveness. By integrating digital health solutions with conventional clinical care, preventive oncology can become more proactive, patient-centered, and scalable. These technologies not only enhance early cancer detection but also empower patients with tools to monitor and modify their risk factors, creating a comprehensive and sustainable framework for preventive care at both individual and population levels.
Session 12: Future Directions and Innovation in Preventive Oncology
The future of preventive oncology lies in integrating technological innovation, precision medicine, and systems-level approaches to dramatically reduce cancer incidence and mortality. Emerging trends include multi-omics profiling, artificial intelligence, predictive analytics, and immunoprevention strategies that allow earlier identification and interception of malignancy. Personalized prevention pathways will increasingly combine genetic, molecular, environmental, and lifestyle data to guide individualized interventions and optimize screening schedules. Novel diagnostic tools such as liquid biopsies, advanced imaging modalities, and real-time wearable biosensors will facilitate continuous risk monitoring and adaptive preventive strategies. Integration of behavioral science, community engagement, and public health policy ensures that innovations are effectively implemented at population scale and reach underserved communities. Ethical considerations, regulatory compliance, and equitable access will remain central to responsible deployment, ensuring that benefits are widely shared and harm is minimized. Collaborative global research networks, translational pipelines, and multi-center clinical trials accelerate the adoption of innovative preventive interventions. The session also explores cost-effectiveness modeling, sustainability frameworks, and health systems integration to ensure that innovations are scalable and deliver measurable outcomes. By combining cutting-edge science, digital health, precision medicine, and public health infrastructure, the future of preventive oncology promises a paradigm shift from reactive treatment to proactive, personalized cancer prevention, ultimately improving survival rates and quality of life worldwide.
Session 13: Psychosocial Oncology and Patient-Centered Preventive Strategies
Integrating psychosocial considerations into preventive oncology is essential for improving patient engagement, adherence, and overall outcomes. Psychological factors such as anxiety, perceived risk, health beliefs, and social support influence individuals’ participation in screening programs, adherence to preventive therapies, and responsiveness to lifestyle interventions. Understanding these behavioral determinants allows clinicians and public health professionals to design personalized, patient-centered strategies that encourage proactive participation in cancer prevention initiatives. Interventions include structured counseling, motivational interviewing, cognitive-behavioral approaches, and peer-support networks aimed at enhancing health literacy and informed decision-making. The session examines strategies for managing distress related to genetic testing, biomarker results, or incidental findings from multi-modal screening, emphasizing ethical communication, shared decision-making, and informed consent. Socioeconomic and cultural factors that contribute to disparities in preventive oncology uptake are addressed, with a focus on tailoring interventions for diverse populations and underserved communities. Technology-assisted psychosocial support, including tele-counseling, mobile apps, and digital communities, is increasingly being used to extend access to mental health and educational resources in real-time. The integration of psychosocial assessment tools into clinical workflows enables continuous monitoring of patient well-being and adherence, facilitating adaptive interventions. By combining behavioral science, community engagement, and patient-centered care models, this session highlights how preventive oncology can move beyond technical diagnostics to address the holistic needs of patients, improve participation in early detection programs, and ultimately enhance long-term health outcomes and quality of life.
Session 14: Nutritional and Lifestyle Interventions in Cancer Prevention
Diet, physical activity, and lifestyle factors are central components of cancer prevention, and targeted interventions can significantly reduce both cancer incidence and progression risk. This session examines evidence-based strategies for dietary modification, including the promotion of plant-based foods, reduction of processed and red meats, moderation of alcohol intake, and maintenance of healthy body weight. Nutritional interventions are linked to the modulation of metabolic pathways, inflammation, hormonal regulation, and gut microbiome composition, all of which influence oncogenesis. Physical activity, encompassing aerobic, resistance, and flexibility exercises, is discussed for its role in reducing cancer risk through improved immune function, regulation of insulin and growth factors, and weight management. Behavioral modification strategies, including goal setting, self-monitoring, motivational interviewing, and structured coaching, support sustained adoption of healthy lifestyles. The session emphasizes culturally sensitive approaches that account for socioeconomic, ethnic, and geographic differences in diet, access to exercise facilities, and health literacy. Community-based programs, school- and workplace-focused interventions, and digital platforms such as mobile apps and wearable trackers are explored as scalable tools to support population-level lifestyle modification. In addition, the session addresses the challenges of adherence, evaluation of program effectiveness, and integration of lifestyle counseling into routine preventive oncology practice. Collaboration between clinicians, dietitians, behavioral scientists, and public health professionals is emphasized to create multi-disciplinary interventions that are both evidence-based and patient-centered. By combining nutritional guidance, physical activity promotion, and behavioral science, lifestyle interventions become a cornerstone of comprehensive cancer prevention strategies, complementing molecular diagnostics, screening, and immunoprevention approaches. This integrated approach not only reduces cancer risk but also improves overall health, quality of life, and long-term wellness outcomes at both the individual and population level.
Session 15: Environmental and Occupational Carcinogen Prevention
Exposure to environmental and occupational carcinogens is a major contributor to cancer incidence worldwide, and targeted prevention strategies are critical for reducing risk. This session examines the identification, monitoring, and mitigation of chemical, physical, and biological carcinogens in workplaces, homes, and communities. Key exposures include asbestos, benzene, polycyclic aromatic hydrocarbons, formaldehyde, heavy metals, ionizing radiation, and certain pesticides, as well as indoor and outdoor air pollution. Participants will explore methods for risk assessment, including biomonitoring, exposure modeling, and epidemiological surveillance, which inform evidence-based regulatory standards and occupational safety protocols. Strategies for prevention encompass policy interventions, such as workplace safety regulations, emission controls, and environmental remediation programs, alongside individual-level measures like personal protective equipment, lifestyle modifications, and education campaigns. The session emphasizes the importance of integrating environmental risk assessment into national cancer prevention frameworks and clinical risk stratification models. Multidisciplinary collaboration between occupational health specialists, industrial hygienists, public health authorities, and policymakers is critical to ensure effective implementation and enforcement. Digital tools and geographic information systems (GIS) are increasingly used to map exposure patterns, track high-risk populations, and design targeted interventions. Special attention is given to vulnerable populations, including children, pregnant women, and low-income communities disproportionately affected by environmental hazards. Ethical, legal, and socioeconomic considerations underpin the development and implementation of preventive strategies, ensuring that interventions are equitable, sustainable, and culturally appropriate. By combining environmental science, occupational health, regulatory policy, and public health practice, this session highlights comprehensive approaches to reducing carcinogen exposure, preventing environmentally induced cancers, and promoting safer workplaces and communities.
Session 16: Implementation Science and Monitoring Outcomes
Effective cancer prevention relies not only on the development of advanced diagnostics and interventions but also on the systematic implementation and evaluation of these strategies in real-world settings. This session focuses on implementation science, which studies the methods and processes that ensure evidence-based preventive oncology practices are adopted, integrated, and sustained across diverse healthcare systems and populations. Participants will examine frameworks for translating research into practice, including the identification of barriers and facilitators at individual, organizational, and policy levels. Key topics include fidelity of intervention delivery, adaptation to local contexts, stakeholder engagement, and integration with existing healthcare infrastructures. Monitoring and evaluation strategies are emphasized to assess both process and outcome metrics, such as screening uptake, adherence to preventive interventions, reduction in cancer incidence, and patient-reported outcomes. Real-world data sources, including electronic health records, cancer registries, mobile health applications, and population surveys, are leveraged to measure effectiveness and inform continuous quality improvement. Cost-effectiveness analysis, health economics modeling, and sustainability planning are incorporated to ensure interventions are scalable and resource-efficient. Special attention is given to equity considerations, addressing disparities in access, engagement, and outcomes among socioeconomically and geographically diverse populations. Collaborative approaches, involving clinicians, public health professionals, policymakers, and community stakeholders, are highlighted as essential to successful implementation. By combining rigorous evaluation, adaptive strategies, and evidence-based planning, implementation science ensures that innovations in preventive oncology translate into meaningful population health benefits. This approach closes the loop from discovery to impact, ensuring that advances in screening, diagnostics, lifestyle interventions, immunoprevention, and digital health are effectively delivered, monitored, and refined to achieve sustainable reductions in cancer burden worldwide.
Session 17: Health Equity and Access in Preventive Oncology
Ensuring equitable access to preventive oncology services is critical for reducing disparities in cancer incidence and outcomes across populations. This session focuses on identifying and addressing systemic, socioeconomic, cultural, and geographic barriers that limit access to screening, early detection, lifestyle interventions, and immunoprevention strategies. Participants will explore strategies for improving health literacy, culturally tailored education programs, and community engagement initiatives designed to empower patients to participate actively in preventive care. Special attention is given to vulnerable populations, including low-income communities, rural residents, racial and ethnic minorities, and individuals with limited digital access. Policy interventions, such as subsidized screening programs, insurance coverage for preventive services, and public health campaigns, are examined as mechanisms to promote equitable access. Integration of digital health tools, telemedicine, and mobile health platforms allows remote populations to receive counseling, monitoring, and follow-up care, bridging gaps in service delivery. The session also emphasizes the role of stakeholder collaboration, involving healthcare providers, community organizations, policymakers, and patient advocates, to design and implement inclusive programs. Metrics and monitoring systems are discussed for evaluating the impact of equity-focused interventions on participation rates, early detection, and long-term cancer outcomes. Ethical considerations, including fairness, resource allocation, and respect for patient autonomy, underpin all strategies for promoting access. By combining public health policy, community-based approaches, digital solutions, and culturally informed practices, this session highlights pathways to achieve health equity in preventive oncology, ensuring that advances in early detection, lifestyle interventions, and immunoprevention benefit all populations, regardless of social or geographic constraints.
Session 18: Genomic Data Integration and Precision Risk Modeling
The integration of genomic data into preventive oncology enables highly personalized risk assessment, early detection, and tailored intervention strategies. This session explores the use of germline and somatic genomic information, polygenic risk scores, and multi-omics datasets to stratify individuals according to cancer susceptibility and inform precision prevention programs. Participants will examine how next-generation sequencing, whole-exome sequencing, and genome-wide association studies provide comprehensive insights into hereditary cancer syndromes, moderate-risk variants, and emerging susceptibility loci. Integration with transcriptomic, proteomic, and epigenetic data allows for dynamic modeling of disease risk and prediction of tumor progression trajectories. Advanced computational tools, including machine learning and predictive algorithms, enable the construction of individualized risk models that combine genetic, environmental, lifestyle, and demographic factors. These models support personalized screening schedules, early intervention strategies, and targeted preventive therapies. Ethical and regulatory considerations, including data privacy, informed consent, and equitable access, are emphasized to ensure responsible use of genomic information. Clinical workflows integrating genomic risk assessment with preventive care protocols are discussed, highlighting the role of genetic counseling, patient education, and shared decision-making. Challenges related to data standardization, interoperability, and interpretation of variants of uncertain significance are addressed, along with strategies to enhance accuracy and clinical utility. By leveraging genomic integration and precision risk modeling, preventive oncology can move beyond population-level screening toward highly individualized strategies that optimize early detection, reduce overdiagnosis, and improve long-term outcomes. This approach represents a key pillar of modern cancer prevention, bridging the gap between molecular science and actionable clinical practice.
Session 19: Advanced Imaging and Radiomics in Early Cancer Detection
Advanced imaging technologies, combined with radiomics and computational analysis, are transforming the early detection of cancer by extracting detailed quantitative information from medical images that goes beyond conventional interpretation. This session explores how modalities such as low-dose computed tomography (CT), magnetic resonance imaging (MRI), positron emission tomography (PET), and hybrid imaging systems can identify subtle morphological, functional, and metabolic changes indicative of early malignancy. Radiomics leverages high-dimensional data extracted from imaging—such as texture, shape, intensity, and spatial relationships—to uncover patterns that correlate with tumor biology, genetic alterations, and clinical outcomes. Machine learning and artificial intelligence algorithms enhance the ability to detect small lesions, differentiate benign from malignant findings, and predict tumor aggressiveness, improving both sensitivity and specificity in screening programs. Integration with multi-omics datasets, including genomics and proteomics, facilitates comprehensive risk assessment and individualized diagnostic pathways. The session also highlights the role of image-guided biopsy, interventional radiology, and longitudinal imaging for monitoring precancerous lesions and treatment response. Quality assurance, standardization of imaging protocols, reproducibility of radiomic features, and validation in multi-center studies are emphasized to ensure clinical utility. Ethical considerations, including patient consent, radiation exposure, incidental findings, and equitable access to advanced imaging, are addressed as part of responsible implementation. Challenges such as data storage, interoperability with electronic health records, and the need for trained multidisciplinary teams are discussed alongside potential solutions. By combining cutting-edge imaging technology with computational analysis, radiomics provides a powerful tool for early cancer detection, enabling personalized surveillance, minimizing invasive procedures, and supporting proactive preventive oncology strategies that improve patient outcomes and optimize healthcare resources.
Session 20: Pharmacologic and Chemopreventive Strategies in Cancer Prevention
Pharmacologic and chemopreventive interventions play a crucial role in reducing cancer risk, particularly for individuals at high genetic, molecular, or environmental susceptibility. This session explores the evidence-based use of drugs and biologics to prevent the initiation, progression, or recurrence of malignancies, integrating molecular profiling, risk stratification, and clinical guidelines. Agents such as selective estrogen receptor modulators (SERMs), aromatase inhibitors, nonsteroidal anti-inflammatory drugs (NSAIDs), and metformin are discussed for their chemopreventive properties in breast, colorectal, and other cancers. Mechanisms of action, including modulation of hormonal pathways, inhibition of inflammatory cascades, suppression of cell proliferation, and induction of apoptosis, are examined to understand how pharmacologic interventions target early carcinogenic processes. The session emphasizes patient selection using biomarkers, genetic testing, and risk models to optimize efficacy and minimize adverse effects. Clinical trial evidence, including randomized controlled studies and long-term follow-up data, is reviewed to guide decision-making in preventive therapy. Safety monitoring, dose optimization, adherence support, and management of side effects are critical components of effective chemoprevention programs. Integration with lifestyle interventions, immunopreventive strategies, and routine screening enhances overall cancer risk reduction. Ethical considerations, including informed consent, patient autonomy, and equitable access, underpin the use of pharmacologic preventive measures. Emerging areas such as targeted small molecules, epigenetic modifiers, and combination preventive regimens are highlighted for their potential to expand personalized prevention. By combining molecular insights, clinical evidence, and individualized risk assessment, pharmacologic and chemopreventive strategies provide a proactive approach to cancer prevention, reducing incidence and improving long-term outcomes while complementing screening, immunoprevention, and lifestyle-based interventions.
Market Analysis
The global cancer diagnostics market has been experiencing steady growth due to rising cancer prevalence and increasing demand for early detection and preventive care. In 2022, the market was valued at approximately USD 147.5?billion, driven by advancements in molecular diagnostics, imaging technologies, and biomarker-based testing. The increasing awareness of cancer prevention and screening programs, along with government and NGO initiatives, has further fueled market expansion across North America, Europe, and Asia-Pacific.
Looking ahead, the market is projected to grow to around USD 238.66?billion by 2030, reflecting a compound annual growth rate (CAGR) of ~6.2?%. Key drivers include the adoption of precision oncology, liquid biopsies, next-generation sequencing, AI-assisted diagnostics, and personalized medicine approaches. Segments like precision oncology diagnostics are expected to grow even faster, from roughly USD 33.2?billion in 2024 to USD 60.2?billion by 2030, highlighting the demand for targeted and accurate diagnostic tools.
Emerging opportunities continue to arise in biomarker profiling, tumor testing, and integrated diagnostic platforms, providing healthcare providers and researchers with advanced solutions for early intervention and treatment planning. With the combination of technological innovation, increased funding, and global awareness, the preventive oncology and cancer diagnostics market is poised for strong, sustained growth through 2030, making it an attractive space for investors, healthcare organizations, and academic research collaborations.
International Societies and Associations:
- Union for International Cancer Control (UICC)
- International Society for Preventive Oncology (ISPO)
- International Society of Nurses in Cancer Care (ISNCC)
- International Society of Clinical Oncology (ISCO)
- Metastasis Research Society (MRS)
- Society for Integrative Oncology (SIO)
- Japanese Cancer Association (JCA)
- European Society of Gynaecological Oncology (ESGO)
- Italian Association of Medical Oncology (AIOM)
Participants & Participation Options
Speaker
- Deliver keynote or invited lectures on preventive oncology, diagnostic innovations, and cancer research.
- Share cutting-edge research, clinical insights, and technological advancements with global delegates.
- Gain professional visibility and networking opportunities with international oncology experts.
Delegate
- Attend scientific sessions, panel discussions, workshops, and networking events.
- Access conference materials, recordings, and interact with experts across preventive oncology and diagnostic cancer fields.
- Engage in knowledge exchange and collaborative discussions with peers.
Poster Presenter
- Showcase original research through printed or digital posters.
- Participate in one-on-one discussions with attendees and experts.
- Gain recognition through DOI publication in conference proceedings.
Exhibitor
- Display products, technologies, or services in dedicated exhibition spaces.
- Connect with delegates, potential clients, collaborators, and research partners.
- Receive professional visibility and feedback from the oncology community.
Video Presentation
- Present research findings or innovations via recorded video sessions.
- Ideal for participants unable to attend in person.
- Maintain international visibility and reach a global audience.
E-Poster Presenter
- Share research electronically through interactive e-posters.
- Participate in virtual discussions and Q&A sessions with attendees.
- Increase accessibility and engagement across global participants.
Virtual Registration
- Attend live-streamed keynote sessions, scientific presentations, and panel discussions online.
- Access conference recordings, digital materials, and virtual networking.
- Ideal for international participants or those unable to attend in person.
- Earn CPD/CME points.
- Networking opportunities with global oncology experts and peers.
- Certificate of participation.
- DOI publication opportunities in conference proceedings.
- Access to cutting-edge research and innovations.
- Professional visibility for speakers, presenters, and exhibitors.
- Opportunities for global collaboration and research partnerships.
- Exposure to advanced cancer prevention and early diagnosis strategies.
Abstract Submission & Registration Timeline
- Abstract Submission Open: Now Open
- Early Bird Registration: February 27, 2026
- Standard Registration: April 27, 2026
- Final Registration Deadline: July 27, 2026
- All abstracts will undergo a peer-review process to ensure scientific quality, relevance, and innovation.
- Authors will receive an Abstract Acceptance Letter confirming inclusion in the conference program.
- Accepted abstracts will be published in the conference proceedings with DOI, ensuring global visibility and citation opportunities.
- Topics include preventive oncology strategies, diagnostic cancer technologies, clinical research, translational medicine, biomarkers, imaging, and public health initiatives.
For questions regarding the 39th Conference on Preventive Oncology and Diagnostic Cancer, abstract submission, registration, or participation, please contact:
- Email: contact@speakermeeting.com
- Phone: +44 2880 090005
- Website: https://preventiveoncology.conferenceseries.com/
-
Social media channels will provide updates, announcements, and conference support.
Past Conference Report
Preventive Oncology 2025
Welcome to the 38th Conference on Preventive Oncology and Diagnostic Cancer, scheduled for May 05-06, 2025, in the beautiful city of Rome, Italy. Preventive Oncology Conference will gather global experts in the fields of oncology, diagnostics, and cancer prevention to discuss innovations and breakthroughs aimed at reducing cancer incidence worldwide. The conference will provide an interdisciplinary platform for scientists, healthcare professionals, industry leaders, and students to share their expertise and collaborate on the most pressing issues in oncology today.
Conference Theme: "Innovative Approaches in Cancer Prevention and Early Diagnosis: Pioneering the Future of Oncology"
The theme of Preventive Oncology 2025 focuses on the critical role of early detection, cutting-edge diagnostic technologies, and preventive strategies in reducing cancer mortality. As cancer remains one of the leading causes of death worldwide, this event aims to foster collaboration and knowledge exchange to drive advancements in prevention and diagnostics, ultimately improving patient outcomes and global health.
Abstract Submission is now open, and we invite researchers and professionals to contribute their latest findings. Early submissions will benefit from reduced registration fees and prioritized presentation opportunities. Ensure to register early to secure your spot at this groundbreaking event!
Past Reports Gallery
To Collaborate Scientific Professionals around the World
Conference Date July 27-28, 2026
For Sponsors & Exhibitors
Speaker Opportunity
Useful Links
Supported By
All accepted abstracts will be published in respective Conference Series International Journals.
Abstracts will be provided with Digital Object Identifier by